Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 24, Issue 7, Pages 783-797
Publisher
Elsevier BV
Online
2023-07-04
DOI
10.1016/s1470-2045(23)00230-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
- (2023) Christopher J Sweeney et al. LANCET ONCOLOGY
- Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium
- (2022) Katharina Beyer et al. EUROPEAN UROLOGY
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
- (2022) Silke Gillessen et al. EUROPEAN UROLOGY
- Estimating interactions and subgroup‐specific treatment effects in meta‐analysis without aggregation bias: A within‐trial framework
- (2022) Peter J. Godolphin et al. Research Synthesis Methods
- Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2021) Ulka N. Vaishampayan et al. JAMA Network Open
- Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer
- (2021) Adnan Ali et al. JAMA Oncology
- Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
- (2021) Hannah L. Rush et al. JOURNAL OF CLINICAL ONCOLOGY
- Individual participant data meta‐analysis to examine interactions between treatment effect and participant‐level covariates: Statistical recommendations for conduct and planning
- (2020) Richard D. Riley et al. STATISTICS IN MEDICINE
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
- (2019) N W Clarke et al. ANNALS OF ONCOLOGY
- What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
- (2018) C L Vale et al. ANNALS OF ONCOLOGY
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
- (2018) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
- (2018) Alicia K. Morgans et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
- (2017) Larysa H.M. Rydzewska et al. EUROPEAN JOURNAL OF CANCER
- A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)
- (2017) M. Smith et al. EUROPEAN UROLOGY SUPPLEMENTS
- Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
- (2017) Malcolm D. Mason et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
- (2017) David J Fisher et al. BMJ-British Medical Journal
- Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
- (2017) David J Fisher et al. BMJ-British Medical Journal
- Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study.
- (2017) I. D. Pedley et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
- (2016) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
- (2016) Claire L Vale et al. LANCET ONCOLOGY
- Should multiple imputation be the method of choice for handling missing data in randomized trials?
- (2016) Thomas R Sullivan et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
- (2014) Gerhardt Attard et al. EUROPEAN UROLOGY
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
- (2012) Matthew R Sydes et al. Trials
- Invited Commentary: G-Computation-Lost in Translation?
- (2011) S. Vansteelandt et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
- (2009) Matthew R Sydes et al. Trials
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started